Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...
Scientists at the University of Michigan Rogel Cancer Center have made a breakthrough in understanding how some prostate cancers transform into aggressive forms that are much harder to treat. The team ...